This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Zimmer Shares Slump on Forecast

OKLAHOMA CITY -- Zimmer (ZMH - Get Report) can't stop the pain.

Shares of the giant orthopedic device maker plunged Thursday after the company endured another miserable quarter -- with its crucial top-line results falling short of Wall Street targets -- as the company struggled to regain its footing following a government crackdown on its business practices. Third-quarter sales rose just 5% to $952 million, missing the $964 million consensus estimate, and would have inched up a mere 2% without help from foreign currency rates.

The company, which routinely boasted double-digit sales growth in the past, now expects sales to rise just 7% to 7.5% over the course of the full year.

Zimmer posted weak profit as well, as the company spent large sums to overhaul its compliance program. While net income rose nearly fivefold to $215 million in the third quarter, due to the absence of a year-ago settlement fee, adjusted earnings crept up a mere 1.4% in the period.

Zimmer did post adjusted earnings per share of 97 cents that beat the consensus estimate of 89 cents, but the market took little comfort in that.

"We are pleased with the considerable progress that we have made on our previously announced operating, infrastructure and compliance initiatives," Zimmer CEO David Dvorak stated early Thursday morning. "Although this transition is negatively impacting our operating results at this point, we are confident that our actions will position us to capture future growth opportunities represented by the markets we serve."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ARTC $48.60 0.08%
ZMH $114.61 0.00%
SYK $92.50 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs